Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma

Journal of Immunological Methods

Volumn 366, Issue 1-2, 2011, Pages 43-51

  Wang, Qiong J ^a   Hanada, Ken ichi ^a   Feldman, Steven A ^a   Zhao, Yangbing ^b   Inozume, Takashi ^a   Yang, James C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adoptive cell transfer; Complementarity determining regions; Genetic modification; Renal cell carcinoma; T cell receptor

Indexed keywords

ALANINE; GAMMA INTERFERON; PHENYLALANINE; RETROVIRUS VECTOR; SERINE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TYROSINE;

ADOPTIVE TRANSFER; AMINO ACID SUBSTITUTION; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA MODIFICATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MOLECULAR RECOGNITION; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; COMPLEMENTARITY DETERMINING REGIONS; DNA PRIMERS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 79952317511     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2011.01.002     Document Type: Article

References (24)

1. Brossart P., Stuhler G., Flad T., Stevanovic S., Rammensee H.G., Kanz L., Brugger W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 1998, 58:732.
2. Cohen C.J., Li Y.F., El Gamil M., Robbins P.F., Rosenberg S.A., Morgan R.A. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007, 67:3898.
3. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850.
4. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., Rogers L.J., Gracia G.J., Jones S.A., Mangiameli D.P., Pelletier M.M., Gea-Banacloche J., Robinson M.R., Berman D.M., Filie A.C., Abati A., Rosenberg S.A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23:2346.
5. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233.
6. Flad T., Spengler B., Kalbacher H., Brossart P., Baier D., Kaufmann R., Bold P., Metzger S., Bluggel M., Meyer H.E., Kurz B., Muller C.A. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. Cancer Res. 1998, 58:5803.
7. Gaudin C., Kremer F., Angevin E., Scott V., Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J. Immunol. 1999, 162:1730.
8. Hanada K., Perry-Lalley D.M., Ohnmacht G.A., Bettinotti M.P., Yang J.C. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res. 2001, 61:5511.
9. Hughes M.S., Yu Y.Y., Dudley M.E., Zheng Z., Robbins P.F., Li Y., Wunderlich J., Hawley R.G., Moayeri M., Rosenberg S.A., Morgan R.A. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 2005, 16:457.
10. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Sherry R.M., Wunderlich J.R., Lee C.C., Restifo N.P., Schwarz S.L., Cogdill A.P., Bishop R.J., Kim H., Brewer C.C., Rudy S.F., VanWaes C., Davis J.L., Mathur A., Ripley R.T., Nathan D.A., Laurencot C.M., Rosenberg S.A. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535.
11. Kuball J., Schmitz F.W., Voss R.H., Ferreira E.A., Engel R., Guillaume P., Strand S., Romero P., Huber C., Sherman L.A., Theobald M. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005, 22:117.
12. Kuball J., Hauptrock B., Malina V., Antunes E., Voss R.H., Wolfl M., Strong R., Theobald M., Greenberg P.D. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J. Exp. Med. 2009, 206:463.
13. Manning T.C., Schlueter C.J., Brodnicki T.C., Parke E.A., Speir J.A., Garcia K.C., Teyton L., Wilson I.A., Kranz D.M. Alanine scanning mutagenesis of an alphabeta T cell receptor: mapping the energy of antigen recognition. Immunity 1998, 8:413.
14. Marrack P., Scott-Browne J.P., Dai S., Gapin L., Kappler J.W. Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu. Rev. Immunol. 2008, 26:171.
15. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126.
16. Robbins P.F., Li Y.F., El Gamil M., Zhao Y., Wargo J.A., Zheng Z., Xu H., Morgan R.A., Feldman S.A., Johnson L.A., Bennett A.D., Dunn S.M., Mahon T.M., Jakobsen B.K., Rosenberg S.A. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 2008, 180:6116.
17. Ronsin C., Chung-Scott V., Poullion I., Aknouche N., Gaudin C., Triebel F. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J. Immunol. 1999, 163:483.
18. Scholten K.B., Kramer D., Kueter E.W., Graf M., Schoedl T., Meijer C.J., Schreurs M.W., Hooijberg E. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin. Immunol. 2006, 119:135.
19. Szymczak A.L., Workman C.J., Wang Y., Vignali K.M., Dilioglou S., Vanin E.F., Vignali D.A. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat. Biotechnol. 2004, 22:589.
20. Vissers J.L., de Vries I.J., Schreurs M.W., Engelen L.P., Oosterwijk E., Figdor C.G., Adema G.J. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 1999, 59:5554.
21. Wang Q.J., Hanada K., Perry-Lalley D., Bettinotti M.P., Karpova T., Khong H.T., Yang J.C. Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor. J. Immunother. 2005, 28:551.
22. Wang Q.J., Hanada K., Yang J.C. Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas. J. Immunol. 2008, 181:3769.
23. Yang J.C., Sherry R.M., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., Hwu P., Seipp C.A., Rogers-Freezer L., Morton K.E., White D.E., Liewehr D.J., Merino M.J., Rosenberg S.A. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 2003, 21:3127.
24. Zhao Y., Zheng Z., Robbins P.F., Khong H.T., Rosenberg S.A., Morgan R.A. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 2005, 174:4415.